Natural IgM Antibodies and Immunosurveillance Mechanisms against Epithelial Cancer Cells in Humans

Cancer Research

Volumn 63, Issue 22, 2003, Pages 7995-8005

  Brändlein, Stephanie ^a   Pohle, Tina ^a   Ruoff, Nele ^a   Wozniak, Ewa ^a   Müller Hermelink, Hans Konrad ^a   Vollmers, H Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M;

ANTIGEN PURIFICATION; ARTICLE; CANCER CELL CULTURE; CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; DNA DETERMINATION; DNA SEQUENCE; EPITHELIUM TUMOR; GERM LINE; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; MOLECULAR RECOGNITION; MUTATION; PRIORITY JOURNAL;

EID: 18544404283     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson, J. D. Cancer. In: M. Robertson, R. Adams, S. M. Cobert, D. Goertzen, (eds.), Molecular Biology of the Cell, Ed. 3 ed., pp. 1255-1291. New York: Garland Publishing, Inc., 1994.
2. Casali, P., and Notkins, A. L. CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol. Today, 10: 364-368, 1989.
3. Vollmers, H. P., and Brändlein, S. Nature's best weapons to fight cancer: reloading human monoclonal IgM antibodies. Hum. Antibodies, 11: 131-142, 2002.
4. Brändlein, S., Lorenz, J., Ruoff, N., Hensel, F., Beyer, I., Müller, J., Neukam, K., Eck, M., Illert, B., Müller-Hermelink, H. K., and Vollmers, H. P. Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients. Hum. Antibodies, 11: 107-119, 2002.
5. Brändlein, S., Beyer, I., Eck, M., Bernhardt, W., Hensel, F., Müller-Hermelink, H. K., and Vollmers, H. P. CFR-1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1. Cancer Res. 63, 2052-2061, 200.
6. Canney, P. A., Moore, M., Wilkinson, P. M., and James, R. D. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br. J. Cancer, 50: 765-769, 1984.
7. Mayer, A., Chester, K. A., Flynn, A. A., and Begent, R. H. Taking engineered anti-CEA antibodies to the clinic. J. Immunol. Methods, 231: 261-273, 1999.
8. de Bono, J. S., and Rowinsky, E. K. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med., 8: 19-26, 2002.
9. Vollmers, H. P., O'Connor, R., Müller, J., Kirchner, T., and Müller-Hermelink, H. K. SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res., 49: 2471-2476, 1989.
10. Pfaff, M., O'Connor, R., Vollmers, H. P., and Muller-Hermelink, H. K. Human monoclonal antibody against a tissue polypeptide antigen-related protein from a patient with a signet-ring cell carcinoma of the stomach. Cancer Res., 50: 5192-5198, 1990.
11. Vollmers, H. P., Dämmrich, J., Ribbert, H., Wozniak, E., and Müller-Hermelink, H. K. Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer (Phila.), 76: 550-558, 1995.
12. Vollmers, H. P., Hensel, F., Hermann, R., Dammrich, J., Wozniak, E., Gessner, P., Herrmann, B., Zimmermann, U., and Muller-Hermelink, H. K. Tumor-specific apoptosis by the human monoclonal antibody SC-1: A new therapeutical approach for stomach cancer. Oncology Reports, 5: 35-40, 1998.
13. Hensel, F., Hermann, R., Schubert, C., Abe, N., Schmidt, K., Franke, A., Shevchenko, A., Mann, M., Muller-Hermelink, H. K., and Volmers, H. P. Characterisation of glycosylphosphatidylinositol-linked molecule CD55/Decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res., 59: 5299-5306, 1999.
14. Hensel, F., Brandlein, S., Eck, M., Schmidt, K., Krenn, V., Kloetzer, A., Bachi, A., Mann, M., Muller-Hermelink, H. K., and Vollmers, H. P. A. novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody. Lab. Investig., 81: 1097-1108, 2001.
15. Hensel, F., Hermann, R., Brandlein, S., Krenn, V., Schmausser, B., Geis, S., Muller-Hermelink, H. K., and Vollmers, H. P. Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis. Lab. Investig., 81: 1553-1563, 2001.
16. Vollmers, H. P., Hensel, F., Hermann, R., Dämmrich, J., Zimmermann, U., and Müller-Hermelink, H. K. Specific apoptotic activity of the human monoclonal antibody SC-1 on the human stomach cancer cells in vitro. Immunobiology, 179: 394, 1997.
17. Vollmers, H. P., Zimmermann, U., Krenn, V., Timmermann, W., Illert, B., Hensel, F., Hermann, R., Thiede, A., Wilhelm, M., Ruckle-Lanz, H., Reindl, L., and Muller-Hermelink, H. K. Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol. Rep., 5: 549-552, 1998.
18. Hermann, R. Hensel, F., Muller, E. C., Keppler, M., Souto-Carneiro, M., Brandlein, S., Muller-Hermelink, H. K., and Vollmers, H. P. Deactivation of regulatory proteins hnRNP A1 and A2 during SC-1 induced apoptosis. Hum. Antibodies, 10: 83-90, 2001.
19. Vollmers, H. P., Dämmrich, J., Hensel, F. Ribbert, H., Meyer-Bahlburg, A., Ufken-Gaul, T., Korff, M., and Müller-Hermelink, H. K. Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Cancer (Phila.), 79: 433-440, 1997.
20. Vollmers, H. P., Dammrich, J., Ribbert, H., Grassel, S., Debus, S., Heesemann, J., and Muller-Hermelink, H. K. Human monoclonal antibodies from stomach carcinoma patients react with Helicobacter pylori and stimulate stomach cancer cells in vitro. Cancer (Phila.), 74: 1525-1532, 1994.
21. Burrus, L. W., Zuber, M. E., Lueddecke, B. A., and Olwin, B. B. Identification of a cysteine-rich receptor for fibroblast growth factors. Mol. Cell. Biol., 12: 5600-5609, 1992.
22. Krenn, V., König, A., Hensel, F., Berek, C., Souto-Carneiro, M. M., Haedicke, W., Wang, Y., Vollmers, H. P., and Müller-Hermelink, H. K. Molecular analysis of rheumatoid factor (RF)-negative B cell hybridomas from rheumatoid synovial tissue: evidence for an antigen-induced stimulation with selection of high mutated IgVH and low mutated IgVL/lambda genes. Clin. Exp. Immunol., 115: 168-175, 1999.
23. Vollmers, H. P., Stulle, K., Dämmrich, J., Pfaff, M., Papadopoulos, T., Betz, C., Saal, K., and Müller-Hermelink, H. K. Characterization of four new gastric cancer cell lines. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol., 63: 335-343, 1993.
24. Saal, K., Vollmers, H. P., Müller, J., Köhler, J., Höhn, H., and Müller-Hermelink, H. K. Cytogenetic differences between intestinal and diffuse types of human gastric carcinoma. Virchows Arch. B. Cell Pathol. Incl. Mol. Pathol., 64: 145-150, 1993.
25. Moretta, A., Bottino, C., Mingari, M. C., Biassoni, R., and Moretta, L. What is a natural killer cell? Nat. Immunol., 3: 6-8, 2000.
26. Amakata, Y., Fujiyama, Y., Andoh, A., Hodohara, K., and Bamba, T. Mechanism of NK cell activation induced by coculture with dendritic cells derived from peripheral blood monocytes. Clin. Exp. Immunol., 124: 214-222, 2001.
27. Soloski, M. J. Recognition of tumor cells by the innate immune system. Curr. Opin. Immunol., 13: 154-162, 2001.
28. Berczi, I., Bertok, L., and Chow, D. A. Natural immunity and neuroimmune host defense. Ann. N. Y. Acad. Sci., 917: 248-257, 2000.
29. Bohn, J. Are natural antibodies involved in tumour defense? Immunol. Lett., 69: 317-320, 1999.
30. Boes, M. Role of natural and immune IgM antibodies in immune responses. Mol. Immunol., 37: 1141-1149, 2000.
31. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., and Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol., 3: 991-998, 2002.
32. Colucci, F., Di Santo, J. P., and Leibson, P. J. Natural killer cell activation in mice and men: different triggers for similar weapons? Nat. Immunol., 3: 807-813, 2002.
33. Kronenberg, M., and Gapin, L. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol., 2: 557-568, 2002.
34. Kuppen, P. J., Gorter, A., Hagenaars, M., Jonges, L. E., Giezeman-Smits, K. M., Nagelkerke, J. F., Fleuren, G., and van de Velde, C. J. Role of NK cells in adoptive immunotherapy of metastatic colorectal cancer in a syngeneic rat model. Immunol. Rev., 184: 236-243, 2001.
35. Parkin, J., and Cohen, B. An overview of the immune system. Lancet, 357: 1777-1789, 2001.
36. Zitvogel, L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J. Exp. Med., 195: 9-14, 2002.
37. MacPherson, G., Kushnir, N., and Wykes, M. Dendritic cells, B cells and the regulation of antibody synthesis. Immunol. Rev., 172: 325-334, 1999.
38. Martin, F., and Kearney, J. F. BI cells: similarities and differences with other B cell subsets. Curr. Opin. Immunol., 13: 195-201, 2001.
39. Ochsenbein, A. F., and Zinkernagel, R. M. Natural antibodies and complement link innate and acquired immunity. Immunol. Today, 21: 624-630, 2000.
40. Moretta, L., Biassoni, R., Bottino, C., Mingari, M. C., and Moretta, A. Natural killer cells: a mystery no more. Scand. J. Immunol., 55: 229-232, 2002.
41. Greenberg, S., and Grinstein, S. Phagocytosis and innate immunity. Curr. Opin. Immunol., 14: 136-145, 2000.
42. Mekori, Y. A., and Metcalfe, D. D. Mast cells in innate immunity. Immunol. Rev., 173: 131-140, 2000.
43. Janeway, C. A., Jr. How the immune system works to protect the host from infection: a personal view. Proc. Natl. Acad. Sci. USA. 98: 7461-7468, 2001.
44. Janeway, C. A., Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol., 54: 1-13, 1989.
45. Medzhitov, R. Toll-like receptors and innate immunity. Nature Rey. Immunol., 1: 135-145, 2001.
46. Cedar, H., and Bergman, Y. Developmental regulation of immune system gene rearrangement. Curr. Opin. Immunol., 11: 64-69, 1999.
47. Lewis, S. M. The mechanism of V(D)J joining: lessons from molecular, immunological, and comparative analyses. Adv. Immunol., 56: 27-150, 1994.
48. Gellert, M. Recent advances in understanding V(D)J recombination. Adv. Immunol., 64: 39-64, 1997.
49. Schatz, D. G., Oettinger, M. A., and Schlissel, M. S. V(D)J recombination: molecular biology and regulation. Annu. Rev. Immunol., 10: 359-383, 1992.
50. Constantinescu, A., and Schlissel, M. S. Changes in locus-specific V(D)J recombinase activity induced by immunoglobulin gene products during B cell development. J. Exp. Med. 185, 609-620, 1997.
51. Papavasiliou, F., Jankovic, M., Gong, S., and Nussenzweig, M. C. Control of immunoglobulin gene rearrangements in developing B cells. Curr. Opin. Immunol., 9: 233-238, 1997.
52. Rothenberg, E. V. Stepwise specification of lymphocyte developmental lineages. Curr. Opin. Genet. Dev., 10: 370-379, 2000.
53. Hensel, F., Knorr, C., Hermann, R., Krenn, V., Muller-Hermelink, H. K., and Vollmers, H. P. Mitogenic autoantibodies in Helicobacter pylori-associated stomach cancerogenesis. Int. J. Cancer, 81: 229-235, 1999.
54. Karsten, U., Diotel, C., Klich, G., Paulsen, H., Goletz, S., Müller, S., and Hanisch, F. G. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation. Cancer Res., 58: 2541-2549, 1998.
55. Egea, G., Franci, C., Gambus, G., Lesuffleur, T., Zweibaum, A., and Real, F. X. cis-Golgi resident proteins and O-glycans are abnormally compartmentalized in the RER of colon cancer cells. J. Cell Sci., 105: 819-830, 1993.
56. Apostolopoulos, V., Loveland, B. E., Pietersz, G. A., and McKenzie, I. F. CTL in mice immunized with human mucin 1 are MHC-restricted. J. Immunol., 155: 5089-5094, 1995.
57. Hayakawa, K., Hardy, R. R., Herzenberg, L. A., and Herzenberg, L. A. Progenitors for Ly-1 B cells are distinct from progenitors for other B cells. J. Exp. Med., 161: 1554-1568, 1985.
58. Kipps, T. J. The CD5 B cell. Adv. Immunol., 47: 117-185, 1989.
59. Forster, I., Gu, H., Muller, W., Schmitt, M., Tarlinton, D., and Rajewsky, K. C. D.5 B cells in the mouse. Curr. Top. Microbiol. Immunol., 173: 247-251, 1991.
60. Hardy, R. R. Variable gene usage, physiology and development of Ly-1+ (CD5+) B cells. Curr. Opin. Immunol., 4: 181-185, 1992.
61. Haughton, G., Arnold, L. W., Whitmore, A. C., and Clarke, S. H. B-1 cells are made, not born. Immunol. Today, 14: 84-87, 1993.
62. Herzenberg, L. A. B-1 cells: the lineage question revisited. Immunol. Rev., 175: 9-22, 2000.
63. Rothstein, T. L. Cutting edge commentary: two B-1 or not to be one. J. Immunol., 168: 4257-4261, 2002.
64. Hayakawa, K., and Hardy, R. R. Development and function of B-1 cells. Curr. Opin. Immunol., 12: 346-353, 2000.
65. Wortis, H. H., and Berland, R. Cutting edge commentary: origins of B-1 cells. J. Immunol., 166: 2163-2166, 2001.
66. Su, I., and Tarakhovsky, A. B-1 cells: orthodox of conformist? Curr. Opin. Immunol., 12: 191-194, 2000.
67. Hayakawa, K., Hardy, R. R., Parks, D. R., and Herzenberg, L. A. The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice. J. Exp. Med., 157: 202-218, 1983.
68. Lalor, P. A., Stall, A. M., Adams, S., and Herzenberg, L. A. Permanent alteration of the murine Ly-1 B repertoire due to selective depletion of Ly-1 B cells in neonatal animals. Eur. J. Immunol., 19: 501-506, 1989.
69. Hamilton, A. M., Lehuen, A., and Kearney, J. F. Immunofluorescence analysis of B-1 cell ontogeny in the mouse. Int. Immunol., 6: 355-361, 1994.
70. Moris, D. L., and Rothstein, T. L. CD5+ B (B-1) cells and immunity. E. C. Snow, Ed. Handbook of B and T Lymphocytes, p. 421. San Diego: Academic, 1994.
71. Lam, K. P., and Rajewsky, K. B cell antigen receptor specificity and surface density together determine B-1 versus B-2 cell development. J. Exp. Med., 190: 471-477, 1999.
72. Sidman, C. L., Shultz, L. D., Hardy, R. R., Hayakawa, K., and Herzenberg, L. A. Production of immunoglobulin isotypes by Ly-1+ B cells in viable motheaten and normal mice. Science (Wash. DC), 232: 1423-1425, 1986.
73. Forster, I., and Rajewsky, K. Expansion and functional activity of Ly-1+ B cells upon transfer of peritoneal cells into allotype-congenic, newborn mice. Eur. J. Immunol., 17: 521-528, 1987.
74. Kroese, F. G., Ammerlaan, W. A., and Kantor, A. B. Evidence that intestinal IgA plasma cells in μ, κ transgenic mice are derived from B-1 (Ly-1 B) cells. Int. Immunol., 5: 1317-1327, 1993.
75. Ishida, H., Hastings, R., Kearney, J., and Howard, M. Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. J. Exp. Med., 175: 1213-1220, 1992.
76. Luhm, J., Brand, J. M., Koritke, P., Hoppner, M., Kirchner, H., and Frohn, C. Large-scale generation of natural killer lymphocytes for clinical application. J. Hematother. Stem. Cell Res., 11: 651-657, 2002.
77. Lanier, L. L., and Phillips, J. H. Natural killer cells. Curr. Opin. Immunol., 4: 38-42, 1992.
78. Miller, J. S. Biology of natural killer cells in cancer and infection. Cancer Investig., 20: 405-419, 2002.
79. Bohn, J. Josimovic-Alasevic, O., Settmacher, U., Kiessig, S. T., Lukowsky, A., Volk, H. D., Diamantstein, T., Von Baehr, R., and Jahn, S. Human monoclonal IgM antibodies from foetal B-cell hybridomas directed against a surface antigen on human tumour cells. Res. Immunol., 143: 879-891, 1992.
80. Ollert, M. W., David, K., Schmitt, C., Hauenschild, A., Bredehorst, R., Erttmann, R., and Vogel, C. W. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc. Natl. Acad. Sci. USA, 93: 4498-503, 1996.
81. David, K., Ollert, M. W., Vollmert, C., Heiligtag, S., Eickhoff, B., Erttmann, R., Bredehorst, R., and Vogel, C. W. Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260, 000 antigen. Cancer Res., 59: 3768-3775, 1999.